Literature DB >> 17502407

Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.

Jeong Hwan Shin1, Hee Jung Jung, Hye Ran Kim, Joseph Jeong, Seok Hoon Jeong, Sunjoo Kim, Eun Yup Lee, Jeong Nyeo Lee, Chulhun Ludgerus Chang.   

Abstract

The genes erm(B), mef(A), and both erm(B) and mef(A) were identified in 42.6, 10.1, and 47.3%, respectively, of the erythromycin-resistant Streptococcus pneumoniae isolates. Of the strains, 3.8% were nonsusceptible to levofloxacin and had 1 to 6 amino acid changes in the quinolone resistance-determining region, including a new mutation, Asn94Ser, in the product of parC. Levofloxacin with reserpine was highly specific for efflux screening.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17502407      PMCID: PMC1913271          DOI: 10.1128/AAC.00107-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.

Authors:  J Broskey; K Coleman; M N Gwynn; L McCloskey; C Traini; L Voelker; R Warren
Journal:  J Antimicrob Chemother       Date:  2000-04       Impact factor: 5.790

Review 2.  Resistance among Streptococcus pneumoniae: Implications for drug selection.

Authors:  Peter C Appelbaum
Journal:  Clin Infect Dis       Date:  2002-05-16       Impact factor: 9.079

3.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.

Authors:  Laura J V Piddock; Maggie M Johnson; S Simjee; L Pumbwe
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.

Authors:  George G Zhanel; Andrew Walkty; Kim Nichol; Heather Smith; Ayman Noreddin; Daryl J Hoban
Journal:  Diagn Microbiol Infect Dis       Date:  2003-01       Impact factor: 2.803

8.  High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).

Authors:  Jae-Hoon Song; Sook-In Jung; Kwan Soo Ko; Na Young Kim; Jun Seong Son; Hyun-Ha Chang; Hyun Kyun Ki; Won Sup Oh; Ji Yoeun Suh; Kyong Ran Peck; Nam Yong Lee; Yonghong Yang; Quan Lu; Anan Chongthaleong; Cheng-Hsun Chiu; M K Lalitha; Jennifer Perera; Ti Teow Yee; Gamini Kumarasinghe; Farida Jamal; Adeeba Kamarulzaman; Navaratnam Parasakthi; Pham Hung Van; Celia Carlos; Thomas So; Tak Keung Ng; Atef Shibl
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

Authors:  R Canton; M Morosini; M C Enright; I Morrissey
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

10.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Authors:  Lionel A Mandell; John G Bartlett; Scott F Dowell; Thomas M File; Daniel M Musher; Cynthia Whitney
Journal:  Clin Infect Dis       Date:  2003-11-03       Impact factor: 9.079

View more
  3 in total

Review 1.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 2.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  A 2011-2012 survey of doctors' perceptions of korean guidelines and empirical treatment of community-acquired pneumonia.

Authors:  Hye-In Kim; Shin-Woo Kim; Hyun-Ha Chang; Jong-Myung Lee; Kyong Ran Peck
Journal:  Infect Chemother       Date:  2013-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.